Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed <i>FLT3</i> Mutated AMLSelina M. Luger, Mark R. Litzow, Mithun Vinod Shah et al.|Blood|2024Cited by 7